REGN – Regeneron Pharmaceuticals Inc 再生元制药

再生元制药公司 (Regeneron Pharmaceuticals Inc) 是一家完全集成的生物技术公司,它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础,并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司,为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。

中文介绍: https://xueqiu.com/S/REGN

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.

英文介绍: https://www.morningstar.com/stocks/xnas/regn/quote

主题测试文章,只做测试使用。发布者:star,转转请注明出处:http://wallstreetgm.com/regn-regeneron-pharmaceuticals-inc-%e5%86%8d%e7%94%9f%e5%85%83%e5%88%b6%e8%8d%af/

发表评论

您的电子邮箱地址不会被公开。 必填项已用*标注